Background: AMG 160 is an HLE BiTE immune therapy that binds prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T cells, leading to T cell activation, cytokine production, and tumor ...

AMG 160 binds to PSMA on cancer cells and CD3 on T cells, leading to T-cell infiltration, activation, expansion, and tumor cell killing. In a first-in-human study, AMG 160 has demonstrated a ...

In this article, ACROBiosystems discusses recent advances in Prostate-Specific Membrane Antigen (PSMA) ... AMG 160 is new HLE-BiTE immunotherapy that possesses a longer half-life, ...

Tran and colleagues aimed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AMG 160 – a targeted half-life extended BiTE (bispecific T-cell engager) immune therapy ...

Amgen will present new data for AMG 510 and AMG 160 during two oral presentations. Data from the study of sotorasib, Amgen' s investigational KRAS G12C inhibitor, will showcase ...

Amgen Inc (NASDAQ: AMGN) has agreed to acquire privately-held Teneobio, a biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Amgen will pay $900 million ...

Amgen’s Teneobio misadventure has taken a $650 million BiTE out of its earnings.The Big Biotech took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in the $900 ...

Amgen will present new data for AMG 510 (proposed INN: sotorasib) and AMG 160 during two oral presentations. Data from the study of sotorasib, Amgen's investigational KRAS G12C inhibitor, will ...